Adjuvant Capital is a life sciences investment firm focused on global health. The firm finances the most promising life science technologies for high-burden public health challenges, leveraging its unique expertise to translate these opportunities into social and financial returns for its investors. They invest primarily in innovative technologies for neglected infectious diseases, maternal and child health, and other crucial public health areas.
Deal activity and portfolio updates would appear here
Connect your data source to see recent transactions